Roy D. Schwarz

1.8k total citations
58 papers, 1.4k citations indexed

About

Roy D. Schwarz is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Organic Chemistry. According to data from OpenAlex, Roy D. Schwarz has authored 58 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Molecular Biology, 34 papers in Cellular and Molecular Neuroscience and 11 papers in Organic Chemistry. Recurrent topics in Roy D. Schwarz's work include Receptor Mechanisms and Signaling (33 papers), Neuroscience and Neuropharmacology Research (21 papers) and Neuropeptides and Animal Physiology (10 papers). Roy D. Schwarz is often cited by papers focused on Receptor Mechanisms and Signaling (33 papers), Neuroscience and Neuropharmacology Research (21 papers) and Neuropeptides and Animal Physiology (10 papers). Roy D. Schwarz collaborates with scholars based in United States, United Kingdom and Australia. Roy D. Schwarz's co-authors include Michael J. Callahan, William J. Lipinski, Robert A. Durham, Feng Bian, Lary C. Walker, Alex E. Roher, Michael D. Kane, Robert E. Davis, Norman J. Uretsky and Joseph R. Bianchine and has published in prestigious journals such as Journal of Neuroscience, Analytical Biochemistry and Biochemical and Biophysical Research Communications.

In The Last Decade

Roy D. Schwarz

58 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Roy D. Schwarz United States 21 819 566 336 284 186 58 1.4k
Т. А. Воронина Russia 17 437 0.5× 447 0.8× 354 1.1× 298 1.0× 161 0.9× 333 1.5k
Uffe Kristiansen Denmark 24 847 1.0× 727 1.3× 150 0.4× 262 0.9× 125 0.7× 64 1.8k
Jiro Itoh Japan 19 695 0.8× 539 1.0× 161 0.5× 251 0.9× 366 2.0× 36 1.5k
R. Ortmann Switzerland 21 720 0.9× 621 1.1× 204 0.6× 77 0.3× 222 1.2× 43 1.4k
James Stoll United States 20 669 0.8× 240 0.4× 448 1.3× 125 0.4× 90 0.5× 32 1.4k
Sonia Poli United States 24 978 1.2× 933 1.6× 289 0.9× 156 0.5× 159 0.9× 45 2.0k
Newton G. Castro Brazil 25 1.4k 1.7× 753 1.3× 208 0.6× 371 1.3× 534 2.9× 47 2.4k
Dominik Feuerbach Switzerland 31 1.4k 1.8× 593 1.0× 282 0.8× 143 0.5× 338 1.8× 75 2.4k
S.T.M. Allard Canada 22 634 0.8× 468 0.8× 675 2.0× 110 0.4× 211 1.1× 39 1.6k
Jane E. SWATTON United Kingdom 15 1.1k 1.4× 341 0.6× 514 1.5× 101 0.4× 167 0.9× 18 2.0k

Countries citing papers authored by Roy D. Schwarz

Since Specialization
Citations

This map shows the geographic impact of Roy D. Schwarz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roy D. Schwarz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roy D. Schwarz more than expected).

Fields of papers citing papers by Roy D. Schwarz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roy D. Schwarz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roy D. Schwarz. The network helps show where Roy D. Schwarz may publish in the future.

Co-authorship network of co-authors of Roy D. Schwarz

This figure shows the co-authorship network connecting the top 25 collaborators of Roy D. Schwarz. A scholar is included among the top collaborators of Roy D. Schwarz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roy D. Schwarz. Roy D. Schwarz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Galatsis, Paul, Cleo J. C. Connolly, John W. Mickelson, et al.. (2007). Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 17(23). 6525–6528. 21 indexed citations
2.
Bove, Susan E., Christopher S. Knauer, Corinne E. Augelli‐Szafran, et al.. (2007). Synthesis and SAR of 2-aryl pyrido[2,3-d]pyrimidines as potent mGlu5 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 17(19). 5396–5399. 22 indexed citations
3.
Tecle, Haile, Roy D. Schwarz, Stephen D. Barrett, et al.. (2000). CI-1017, a functionally M1-selective muscarinic agonist: design, synthesis, and preclinical pharmacology. Pharmaceutica Acta Helvetiae. 74(2-3). 141–148. 11 indexed citations
4.
Kane, Michael D., Roy D. Schwarz, M. Desiree Watson, et al.. (1999). Inhibitors of V‐Type ATPases, Bafilomycin A1 and Concanamycin A, Protect Against β‐Amyloid‐Mediated Effects on 3‐(4,5‐Dimethylthiazol‐2‐yl)‐2,5‐Diphenyltetrazolium Bromide (MTT) Reduction. Journal of Neurochemistry. 72(5). 1939–1947. 19 indexed citations
5.
Augelli‐Szafran, Corinne E., et al.. (1998). Identification and characterization of m4 selective muscarinic antagonists. Bioorganic & Medicinal Chemistry Letters. 8(15). 1991–1996. 35 indexed citations
6.
7.
Augelli‐Szafran, Corinne E., et al.. (1997). Functional characterisation of PD102807: A novel M4-selective muscarinic antagonist. Life Sciences. 60(13-14). 1168–1168. 6 indexed citations
8.
Schwarz, Roy D., Juan C. Jaén, Tara Mirzadegan, et al.. (1995). Mutations of aspartate 103 in the Hm2 receptor and alterations in receptor binding properties of muscarinic agonists. Life Sciences. 56(11-12). 923–929. 13 indexed citations
9.
Jaén, Juan C., Stephen D. Barrett, Mark R. Brann, et al.. (1995). In vitro and in vivo evaluation of the subtype-selective muscarinic agonist PD 151832. Life Sciences. 56(11-12). 845–852. 18 indexed citations
10.
Sedman, Allen J., Howard N. Bockbrader, & Roy D. Schwarz. (1995). Preclinical and Phase 1 clinical characterization of CI-979/ RU35926, a novel muscarinic agonist for the treatment of Alzheimer's disease. Life Sciences. 56(11-12). 877–882. 27 indexed citations
11.
Emmerling, Mark R., V. Gregor, Roy D. Schwarz, et al.. (1994). PD 142676 (CI 1002), a novel anticholinesterase and muscarinic antagonist. Molecular Neurobiology. 9(1-3). 93–106. 9 indexed citations
12.
Hays, Sheryl J., et al.. (1994). Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. Journal of Medicinal Chemistry. 37(2). 268–274. 20 indexed citations
13.
Davis, Robert E., C Raby, Michael J. Callahan, et al.. (1993). Chapter 54: Subtype selective muscarinic agonists: potential therapeutic agents for Alzheimer's disease. Progress in brain research. 98. 439–445. 19 indexed citations
14.
Tecle, Haile, Tara Mirzadegan, Walter H. Moos, et al.. (1993). Synthesis and Sar of bulky 1-azabicyclo[2.2.1]-3-one oximes as muscarinic receptor subtype selective agonists. Life Sciences. 52(5-6). 505–511. 18 indexed citations
15.
Schwarz, Roy D., et al.. (1993). Characterization of muscarinic agonists in recombinant cell lines. Life Sciences. 52(5-6). 465–472. 34 indexed citations
16.
Moos, Walter H., Stephen C. Bergmeier, Linda L. Coughenour, et al.. (1992). Cholinergic Agents: Effect of Methyl Substitution in a Series of Arecoline Derivatives on Binding to Muscarinic Acetylcholine Receptors. Journal of Pharmaceutical Sciences. 81(10). 1015–1019. 5 indexed citations
17.
Schwarz, Roy D., et al.. (1991). Next generation tacrine. Neurobiology of Aging. 12(2). 185–187. 9 indexed citations
18.
Kiely, John S., et al.. (1991). A silica gel plate-based qualitative assay for acetylcholinesterase activity: A mass method to screen for potential inhibitors. Analytical Biochemistry. 196(2). 439–442. 18 indexed citations
19.
Schwarz, Roy D., et al.. (1990). Loss of muscarinic M1 receptors with aging in the cerebral cortex of fisher 344 rats. Pharmacology Biochemistry and Behavior. 35(3). 589–593. 27 indexed citations
20.
Moos, Walter H., Robert E. Davis, Roy D. Schwarz, & Elkan Gamzu. (1988). Cognition activators. Medicinal Research Reviews. 8(3). 353–391. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Т. А. Воронина Breakdown of academic impact, for papers by Uffe Kristiansen Breakdown of academic impact, for papers by Jiro Itoh Breakdown of academic impact, for papers by R. Ortmann Breakdown of academic impact, for papers by James Stoll Breakdown of academic impact, for papers by Sonia Poli Breakdown of academic impact, for papers by Newton G. Castro Breakdown of academic impact, for papers by Dominik Feuerbach Breakdown of academic impact, for papers by S.T.M. Allard Breakdown of academic impact, for papers by Jane E. SWATTON
Rankless by CCL
2026